Based on the above reports, we choose SREBP-2, HMGCR, and FPPS as potential targets for cancer therapy and summarized the findings so far regarding several inhibitors or miRNAs used to address these targets in preclinical and clinical studies. The gene discussed is FDPS; the disease is cancer.